Vutrisiran ATTR Cm denied as not FDA-approved for this use by Cigna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Vutrisiran ATTR Cm
## Why Cigna May Issue a Not-FDA-Approved Denial for Vutrisiran (ATTR-CM) — and Why You Can Appeal
Vutrisiran (Amvuttra) is FDA-approved for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). A "not-FDA-approved" denial from Cigna almost always reflects one of three administrative errors: (1) Cigna's internal policy has not been updated to reflect the current FDA-approved labeling; (2) the claim was coded in a way that did not match the approved indication; or (3) the prior authorization submission did not explicitly reference the approved indication. In each case, the path forward is the same — provide direct evidence of FDA approval and the match between your diagnosis and that approved indication.
## Why This Denial Is Appealable
This denial type is one of the most straightforwardly reversible. FDA approval is a matter of public regulatory record. Under ACA §2719, you have the right to a full internal appeal and then an independent external review. Under ERISA §503 (for employer-sponsored plans), the plan must provide a full-and-fair review of the clinical and regulatory basis for the denial. Independent external reviewers routinely reverse "not-FDA-approved" denials when the submitting party provides the FDA label. The external review window is typically available for approximately four months after a final internal denial, and expedited review is available when your health is at risk.
## What to Gather
- Current FDA prescribing label: Download the full prescribing information for vutrisiran directly from the FDA website. Highlight the approved indication and confirm it matches your diagnosis. This is your single most important document.
- Diagnosis confirmation: Cardiologist notes, nuclear imaging, biopsy, or genetic testing confirming ATTR-CM.
- Prescriber cover letter: A brief letter from your cardiologist stating that vutrisiran is being prescribed for its FDA-approved indication as documented in the attached label.
- Diagnosis coding review: Ask your cardiologist's office to confirm that the ICD-10 diagnosis code submitted on the prior authorization matches the approved indication. A coding mismatch is a common and correctable cause of this denial type.
- Cigna's denial basis: Request the exact written basis for the "not-FDA-approved" determination so you can address it specifically.
## Criteria-Mapping Structure
Address the denial directly and concisely:
> Cigna's stated basis: [paste verbatim from denial letter] > Rebuttal: [FDA label approval date, indication statement, and chart confirmation of your ATTR-CM diagnosis]
## Timeline
File your internal appeal as soon as possible — confirm the exact deadline in your denial letter. Given the administrative nature of this denial, it may resolve at the internal-appeal level without reaching external review. However, if the internal appeal is denied, file for external review immediately to preserve your rights within the approximately four-month window.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →